Eli Lilly files six lawsuits over black-market retatrutide sales

Eli Lilly filed six new lawsuits against U.S. companies allegedly selling black-market versions of its investigational weight-loss drug retatrutide, which remains in Phase 3 clinical trials and has not been approved by any regulator for human use. The company also referred hundreds of bad actors to regulators and law enforcement worldwide.

Detected & updated continuously · Source: Nebula

Story subjects

Eli LillyRetatrutideUnited States

Track sentiment and mindshare across stocks and crypto in Nebula.

Open Nebula